Midi’s public HRT service is organized around virtual clinician visits and a personalized care plan. It describes FDA-approved bioidentical menopause hormones and publishes both insurance information and self-pay visit prices.
A different page describes compounded testosterone for women. That separation is important: a service can offer approved and compounded treatments under one name, and insurance or state availability for one part of the service does not establish availability for another.
In this entry
The appointment framework
Midi describes an initial discussion of symptoms and medical history before selecting treatment. Its HRT information discusses formulation, dose selection and later adjustments. For a reader with several questions, a scheduled conversation may be a more comfortable entry point than beginning with a product selection.
Ask what the appointment can address and what falls outside the service. Menopause symptoms can overlap with other conditions, and some problems need a physical examination, testing or another specialist. Clarify how the clinician communicates with your local care team and how you can obtain a copy of the plan.
Put insurance claims to a specific test
Midi says it participates with most PPO plans, with coverage depending on the plan. Verify the actual insurer, plan, state, clinician and appointment type. A deductible can make a covered visit cost more than expected, and pharmacy benefits are a separate consideration.
The public HRT page also describes restrictions involving Medicaid and Medicare. It states that Medicaid and Medi-Cal patients cannot currently be treated, even as self-pay, and that Medicare beneficiaries can be seen as self-pay with restrictions on submitting claims for Midi-related services. Readers near Medicare age should check the current policy directly before scheduling.
The self-pay figures
The listed initial visit price was $250 and continued-care visits were $150 at our check. Medication and testing should not be assumed included. An initial appointment plus one follow-up would therefore be $400 in visit charges at those published rates, before other items.
That calculation is a comparison example, not a prediction of how many visits you will need. Ask the clinician about the expected cadence and the billing team about charges for messages, refills or additional concerns. The cost guide separates these categories so an insurance estimate can be compared with a cash-pay quote.
Testosterone is not simply another estrogen option
Midi describes its testosterone product as compounded and not FDA-approved. It also notes the absence of a US FDA-approved testosterone formulation specifically indicated for women. This is a separate prescribing discussion from using approved estrogen and progesterone for menopause symptoms.
Ask what condition is being treated, what evidence supports the proposed use and how excessive exposure is avoided. Do not assume that broad marketing around energy, mood or strength demonstrates benefit for every woman. Our testosterone evidence brief explains the narrower questions worth taking to a qualified clinician.
Availability needs a medication-level answer
National virtual care can coexist with a narrower state list for a particular medication. Check the testosterone program’s actual availability rather than relying on the HRT service’s general footprint. Travel and a change of residence may also affect the care arrangement.
If tests are needed, ask which laboratory performs them, what they cost and how results affect treatment. A monitoring plan should explain decisions, not simply collect numbers. Ask how adverse effects are handled between visits and what would lead to stopping the medicine.
Estrogen care still needs a complete history
Discuss whether symptoms call for systemic treatment, local vaginal therapy or another option. If you have a uterus and systemic estrogen is proposed, the regimen should address endometrial protection. Include previous cancers, clots, stroke, heart disease, liver disease and unexplained bleeding in the history.
Starting later in life calls for particular attention to timing and risk. The over-50 decision guide explains why a provider’s convenience cannot determine the clinical choice.
Our comparison note
Midi is worth examining for scheduled menopause care and potential insurance use. Gennev is a useful comparison for doctor visits, and Evernow for mixed visit and membership access. We have not verified appointment wait times, claim processing, individual clinician quality or treatment outcomes. The written plan and your confirmed financial responsibility should carry more weight than a general promise of coverage.
CHECK THE ORIGINAL
The source record
Provider pages document their own offers. Medical and regulatory sources provide treatment context. This is not a record of personal patient testing. All sources checked September 20, 2026.